FR3125965B1 - Conjugués anticorps-médicament - Google Patents

Conjugués anticorps-médicament Download PDF

Info

Publication number
FR3125965B1
FR3125965B1 FR2108537A FR2108537A FR3125965B1 FR 3125965 B1 FR3125965 B1 FR 3125965B1 FR 2108537 A FR2108537 A FR 2108537A FR 2108537 A FR2108537 A FR 2108537A FR 3125965 B1 FR3125965 B1 FR 3125965B1
Authority
FR
France
Prior art keywords
antibody
drug conjugates
conjugate
relates
autoantibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2108537A
Other languages
English (en)
Other versions
FR3125965A1 (fr
Inventor
Camille Martin
Ofelia Feuillâtre
Yves Gruel
Jérôme Rollin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mc Saf Fr
Centre Hospitalier Regional Universitaire de Tours
Universite de Tours
Original Assignee
Mc Saf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mc Saf filed Critical Mc Saf
Priority to FR2108537A priority Critical patent/FR3125965B1/fr
Priority to PCT/FR2022/051554 priority patent/WO2023012437A1/fr
Priority to CA3227955A priority patent/CA3227955A1/fr
Priority to EP22760765.2A priority patent/EP4380625A1/fr
Priority to CN202280065825.4A priority patent/CN118251239A/zh
Publication of FR3125965A1 publication Critical patent/FR3125965A1/fr
Application granted granted Critical
Publication of FR3125965B1 publication Critical patent/FR3125965B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L’invention concerne un conjugué comprenant a) un anticorps ou un fragment d’anticorps, et b) une protéase spécifique de la région charnière des immunoglobulines G (IgG). L’invention concerne également une composition comprenant au moins un tel conjugué, ainsi que l’utilisation de ce conjugué comme médicament, en particulier pour le traitement d’une maladie induite par des auto-anticorps.
FR2108537A 2021-08-05 2021-08-05 Conjugués anticorps-médicament Active FR3125965B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR2108537A FR3125965B1 (fr) 2021-08-05 2021-08-05 Conjugués anticorps-médicament
PCT/FR2022/051554 WO2023012437A1 (fr) 2021-08-05 2022-08-04 Conjugués anticorps-médicament
CA3227955A CA3227955A1 (fr) 2021-08-05 2022-08-04 Conjugues anticorps-medicament
EP22760765.2A EP4380625A1 (fr) 2021-08-05 2022-08-04 Conjugués anticorps-médicament
CN202280065825.4A CN118251239A (zh) 2021-08-05 2022-08-04 抗体-药物缀合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2108537 2021-08-05
FR2108537A FR3125965B1 (fr) 2021-08-05 2021-08-05 Conjugués anticorps-médicament

Publications (2)

Publication Number Publication Date
FR3125965A1 FR3125965A1 (fr) 2023-02-10
FR3125965B1 true FR3125965B1 (fr) 2024-06-21

Family

ID=78086496

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2108537A Active FR3125965B1 (fr) 2021-08-05 2021-08-05 Conjugués anticorps-médicament

Country Status (5)

Country Link
EP (1) EP4380625A1 (fr)
CN (1) CN118251239A (fr)
CA (1) CA3227955A1 (fr)
FR (1) FR3125965B1 (fr)
WO (1) WO2023012437A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008408B1 (fr) * 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
CN116920115A (zh) * 2018-12-17 2023-10-24 荣昌生物制药(烟台)股份有限公司 一种用于抗体药物偶联物的连接子及其应用
FR3096259B1 (fr) * 2019-05-20 2023-12-15 Mc Saf conjugués anticorps-médicament et leur utilisation en thérapie
FR3112547B1 (fr) * 2020-07-20 2023-01-20 Mc Saf Composés capables de se lier à des protéines et conjugués obtenus à partir de ces composés

Also Published As

Publication number Publication date
CA3227955A1 (fr) 2023-02-09
EP4380625A1 (fr) 2024-06-12
CN118251239A (zh) 2024-06-25
FR3125965A1 (fr) 2023-02-10
WO2023012437A1 (fr) 2023-02-09

Similar Documents

Publication Publication Date Title
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA54405B1 (fr) Anticorps de la glycoprotéine de spicule anti-sras-cov-2 et fragments de liaison à l'antigène
DK1140170T3 (da) Antistoffragmenter til topisk behandling af öjensygdomme
MA30163B1 (fr) Anticorps monoclonaux specifiques pour a beta 1-42 ayant des proprietes therapeutiques
MA33387B1 (fr) Polypeptides et procede de traitement
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
MA40041B1 (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
TR200200472T2 (tr) Anti-Erb B2 antikorları ile tedavi için dozajlar
MA35659B1 (fr) Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer
MA29374B1 (fr) Anticorps anti-ccr5 et leurs utilisations
MA32099B1 (fr) Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci
MA31886B1 (fr) Anticorps anti-hepcidine et utilisations de ceux-ci
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha
TNSN04078A1 (fr) Antibodies to cd40
MA33285B1 (fr) Anticorps anti-cxcr4 pour le traitement du vih
MA27773A1 (fr) Preparations d'anticorps et de proteines a forte concentration
MA33221B1 (fr) Fusions de médicament et conjugués afférents
MA54975B1 (fr) Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
MA39378B2 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
MX2021010003A (es) Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
MA53765A1 (fr) Tubulysines et conjugués tubulysines-protéines
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
FR3125965B1 (fr) Conjugués anticorps-médicament

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20230210

TQ Partial transmission of property

Owner name: CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE T, FR

Effective date: 20230302

Owner name: UNIVERSITE DE TOURS, FR

Effective date: 20230302

Owner name: MC SAF, FR

Effective date: 20230302

PLFP Fee payment

Year of fee payment: 3